Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

GSK seeks EU approval for Trelegy in adult asthma patients

GSK seeks EU approval for Trelegy in adult asthma patients

GSK also has another medicine – Nucala – which is approved for use in severe eosinophilic asthma, although the potential Trelegy indication would open up a larger market.

Latest news

More from news
Approximately 2 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    It also plans to achieve the first FDA therapy approval to treat eosinophilic oesophagitis, a chronic, allergic condition with little current respite.

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    mepolizumab to treat COPD exacerbations with eosinophilic inflammation. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    GSK is also anticipating data in hyper-eosinophilic syndrome and nasal polyposis which could lead to commercial approvals in both by the end of 2020. ... Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics